These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 25576149)

  • 21. Quantitative high throughput analytics to support polysaccharide production process development.
    Noyes A; Godavarti R; Titchener-Hooker N; Coffman J; Mukhopadhyay T
    Vaccine; 2014 May; 32(24):2819-28. PubMed ID: 24576849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. From cell line development to the formulated drug product: The art of manufacturing therapeutic monoclonal antibodies.
    Carrara SC; Ulitzka M; Grzeschik J; Kornmann H; Hock B; Kolmar H
    Int J Pharm; 2021 Feb; 594():120164. PubMed ID: 33309833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-throughput assessment of thermal and colloidal stability parameters for monoclonal antibody formulations.
    He F; Woods CE; Becker GW; Narhi LO; Razinkov VI
    J Pharm Sci; 2011 Dec; 100(12):5126-41. PubMed ID: 21789772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting Colloidal Stability of High-Concentration Monoclonal Antibody Formulations in Common Pharmaceutical Buffers Using Improved Polyethylene Glycol Induced Protein Precipitation Assay.
    Meza NP; Hardy CA; Morin KH; Huang C; Raghava S; Song J; Zhang J; Wang Y
    Mol Pharm; 2023 Nov; 20(11):5842-5855. PubMed ID: 37867303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-throughput development of amphiphile self-assembly materials: fast-tracking synthesis, characterization, formulation, application, and understanding.
    Mulet X; Conn CE; Fong C; Kennedy DF; Moghaddam MJ; Drummond CJ
    Acc Chem Res; 2013 Jul; 46(7):1497-505. PubMed ID: 23427836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality by Design Approaches to Formulation Robustness-An Antibody Case Study.
    Wurth C; Demeule B; Mahler HC; Adler M
    J Pharm Sci; 2016 May; 105(5):1667-1675. PubMed ID: 27001536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of a High Throughput and Automated Workflow to Therapeutic Protein Formulation Development.
    Ren CD; Qi W; Wyatt EA; Yeary J; Westland K; Berke M; Rathore N
    J Pharm Sci; 2021 Mar; 110(3):1130-1141. PubMed ID: 33203511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of protein degradation during vibrating mesh nebulization via a high throughput screening method.
    Hertel S; Pohl T; Friess W; Winter G
    Eur J Pharm Biopharm; 2014 Jul; 87(2):386-94. PubMed ID: 24709473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of preformulation on drug development.
    Bharate SS; Vishwakarma RA
    Expert Opin Drug Deliv; 2013 Sep; 10(9):1239-57. PubMed ID: 23534681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent development in software and automation tools for high-throughput discovery bioanalysis.
    Shou WZ; Zhang J
    Bioanalysis; 2012 May; 4(9):1097-109. PubMed ID: 22612689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Orthogonal Methods for Characterizing the Unfolding of Therapeutic Monoclonal Antibodies: Differential Scanning Calorimetry, Isothermal Chemical Denaturation, and Intrinsic Fluorescence with Concomitant Static Light Scattering.
    Temel DB; Landsman P; Brader ML
    Methods Enzymol; 2016; 567():359-89. PubMed ID: 26794361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aggregates in monoclonal antibody manufacturing processes.
    Vázquez-Rey M; Lang DA
    Biotechnol Bioeng; 2011 Jul; 108(7):1494-508. PubMed ID: 21480193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Shipping-Induced Aggregation in Therapeutic Antibodies: Utilization of a Scale-Down Model to Assess Degradation in Monoclonal Antibodies.
    Fleischman ML; Chung J; Paul EP; Lewus RA
    J Pharm Sci; 2017 Apr; 106(4):994-1000. PubMed ID: 27964939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. State-of-the-art in downstream processing of monoclonal antibodies: process trends in design and validation.
    Marichal-Gallardo PA; Alvarez MM
    Biotechnol Prog; 2012 Jul; 28(4):899-916. PubMed ID: 22641473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of critical quality attributes for monoclonal antibodies using quality by design principles.
    Alt N; Zhang TY; Motchnik P; Taticek R; Quarmby V; Schlothauer T; Beck H; Emrich T; Harris RJ
    Biologicals; 2016 Sep; 44(5):291-305. PubMed ID: 27461239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virus-like particle formulation optimization by miniaturized high-throughput screening.
    Mohr J; Chuan YP; Wu Y; Lua LH; Middelberg AP
    Methods; 2013 May; 60(3):248-56. PubMed ID: 23639868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Label-free screening assays: a strategy for finding better drug candidates.
    Lunn CA
    Future Med Chem; 2010 Nov; 2(11):1703-16. PubMed ID: 21428840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive Nature of High-Throughput Assays in ADC Formulation Screening.
    Mills BJ; Godamudunage MP; Ren S; Laha M
    J Pharm Sci; 2023 Jul; 112(7):1821-1831. PubMed ID: 37037342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a high-throughput solubility screening assay for use in antibody discovery.
    Chai Q; Shih J; Weldon C; Phan S; Jones BE
    MAbs; 2019; 11(4):747-756. PubMed ID: 30913963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.